

Docket No. 0475-0205P

REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application.

The claims have been amended to remove the improper multiple dependencies in order to place the application into better form prior to examination.


Entry of the above amendments is earnestly solicited. An early and favorable first action on the merits is earnestly solicited.

Attached hereto is a marked-up version showing the changes made to the application by this Amendment.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By  #32,868  
Andrew D. Meikle, #32,868

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

ADM/nv  
0475-0205P

**Attachment: VERSION WITH MARKINGS TO SHOW CHANGES MADE**

(Rev. 02/21/02)

Docket No. 0475-0205P

VERSION WITH MARKINGS TO SHOW CHANGES MADEIN THE CLAIMS:

The claims have been amended as follows:

4. (Amended) Elastomer material according to [one of claims 1 to 3] claim 1, characterized in that the ratio of number of mols of boron in the catalyst component to the number of aziridino equivalents in the mixed preparation is 1 : 1 to 1 : 20.

5. (Amended) Elastomer material according to [one of claims 1 to 4] claim 1, characterized in that the boric acid complexes are prepared by reaction of boric acid or boric acid derivatives with compounds which contain at least two OH groups or in that the boric acid complexes are prepared by reaction of boric acid esters with compounds which contain at least two OH groups.

6. (Amended) Elastomer material according to [one of claims 1 to 5] claim 1, characterized in that the reaction of the boric acid or the boric acid derivative with the OH-functional compounds is carried out before the formulation of the catalyst component and the ester-like boric acid complex is used as a constituent of the catalyst component, or in that the reaction of the boric acid or the boric acid derivative with the OH-functional compounds takes place during the formulation of the

Docket No. 0475-0205P

catalyst component, or in that the reaction of the boric acid or the boric acid derivative with the OH-functional compounds takes place during and after the mixing of the catalyst component with the base component.

7. (Amended) Elastomer material according to [one of claims 1 to 6] claim 1, characterized in that the formation of the curing-triggering boric acid complex takes place during and/or after the mixing of the catalyst component with the base component from a boric acid derivative of the catalyst component and at least one OH-functional compound with at least 2 OH groups of the base component.

8. (Amended) Elastomer material according to [one of claims 1 to 7] claim 1, characterized in that the formation of the curing-triggering boric acid complex takes place during and/or after the mixing of the catalyst component with the base component at least partly from a boric acid derivative, preferably a boric acid ester, of the catalyst component and at least one OH-functional compound of the base component.

9. (Amended) Elastomer material according to [one of claims 1 to 8] claim 1, characterized in that a molar ratio between boric acid and the OH-functional compounds of 1 : 0.1 to 1 : 10, preferably 1 : 1 to 1 : 4 and particularly preferably of 1 : 1.5 to 1 : 3 is established.

Docket No. 0475-0205P

10. (Amended) Elastomer material according to [one of claims 1 to 9] claim 1, characterized in that, as complexing agent for the boric acid, OH-functional organic compounds are used which contain at least one 1,2-dihydroxy and/or at least one 1,3-dihydroxy group.

11. (Amended) Elastomer material according to [one of claims 1 to 10] claim 1, characterized in that OH-functional complexing agents are used which have at least one phenolic OH group.

13. (Amended) Elastomer material according to [one of claims 1 to 12] claim 1, characterized in that, as complexing agent,  $\alpha$ -hydroxycarboxylic acids and preferably glycolic acid, mandelic acid and benzilic acid are used.

14. (Amended) Elastomer material according to [one of claims 1 to 13] claim 1, characterized in that, as complexing agents, compounds with protected and preferably silylated OH groups are used.

15. (Amended) Elastomer material according to [one of claims 1 to 14] claim 1, characterized in that several complexing agents are used.

Docket No. 0475-0205P

16. (Amended) Elastomer material according to [one of claims 1 to 15] claim 1, characterized in that combinations of boric acid complexes with varying structure and composition are used.

18. (Amended) Elastomer material according to [one of claims 1 to 17] claim 1, characterized in that the boric acid complexes are used together with other starters and preferably with sulphonium starters.

20. (Amended) Use of elastomer materials according to [one of claims 1 to 18] claim 1 for dental [modelling] modeling, as bite-registration materials or as doubling materials.

21. (Amended) Kit which contains the base component and the catalyst component according to [one of claims 1 to 18] claim 1 separately from each other.